WuXi Biologics to build U.S. plant as it rapidly moves beyond its China base

WuXi Biologics plant
WuXi Biologics will build a plant in the Boston area, its third outside of China and its 11th plant in its manufacturing network. (WuXi)

China’s WuXi Biologics, which is trying to rapidly establish itself as a biologics CDMO with global reach, says it will build a manufacturing operation in the U.S. The announcement comes just two months after it said it would build a plant in Europe, that one its first outside of China.

The company today said it will invest $60 million to build a clinical and commercial scale biologics plant in in Worcester, Massachusetts, which it says will employ about 150.

“Metropolitan Boston is acknowledged as a leader in the biopharmaceutical industry. The new site plays a key role in WuXi Biologics’ global bio-manufacturing network to ensure that biologics are manufactured at the highest quality and within a robust supply chain to benefit patients worldwide,” Ge Li, WuXi Biologics chairman said in a statement.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

RELATED: China's WuXi Biologics to build biologics plant in Ireland

The project, which is getting financial support from several state and local development groups, will have approximately 4,500 L bioreactor capacity, which will include two 2,000 L traditional fed-batch and one 500 L perfusion-based continuous processing units. This facility will handle both clinical and small volume commercial production. An early-stage bioprocess development lab will also be included.

In April, Wuxi-city based WuXi Biologics said it would lay out €325 million ($392 million) to build a biologics facility in Dundalk, Ireland, and create a campus of 26 hectares (2.8 million square feet). The project, its first outside of China, has been in the works for several years and has snagged support from Ireland’s development agency. That plant will eventually employ 400.

A month later, it announced a second facility to be built outside of China, this one in Singapore. That facility is more in line in size with its U.S. endeavor. It is expected to cost about $60 million to erect the facility and eventually will employ 150. It will be its first Asian plant built outside of China.

RELATED: WuXi and Sinobioway add capacity to nab expected wave of Chinese biologics

On top of all of that, WuXi Biologics in May said it intended to erect an R&D and clinical and commercial production center in Shijiazhuang, China, that will eventually employ 1,000 workers. The company will invest $240 million in the new facility, which will have a 48,000-liter bioreactor capacity. Work is to begin next year, and the first phase is to be completed in 2020.

Suggested Articles

Industry watchers have been speculating about just how high Novartis would price gene therapy Zolgensma. And now, they have an answer.

The WHO’s role in part is to provide prescribing guidance without an eye on profits. What happens when that guidance is tainted by private money?

After 19 sales reps left Amgen to help Karyopharm launch a rival multiple myeloma drug, Amgen sued. Now Karyopharm wants the suit thrown out.